NCT04880616View on ClinicalTrials.gov

Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 20, 2021

Primary Completion Date

May 25, 2022

Study Completion Date

June 8, 2022

Conditions
Essential Tremor
Interventions
DRUG

NBI-827104

Capsules for oral administration

DRUG

Placebo

Capsules matching NBI-827104 for oral administration

Trial Locations (1)

2333

Neurocrine Clinical Site, Leiden

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY